Author Correction: Propensity of selecting mutant parasites for the antimalarial drug cabamiquine

Affiliations

• ¹ The Kirby Institute, UNSW Sydney, Kensington, NSW, 2052, Australia.
• ² Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Faculté de Pharmacie, Malaria Research and Training Center (MRTC), Point G, PB1805, Bamako, Mali.
• ³ Medicinal Chemistry & Drug Design Global Research & Development, Discovery Technologies, Merck Healthcare, 64293, Darmstadt, Germany.
• ⁴ Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
• ⁵ Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY, 10032, USA.
• ⁶ Global Health Institute of Merck, Ares Trading S.A., (an affiliate of Merck KGaA, Darmstadt, Germany), 1262, Eysins, Switzerland.
• ⁷ Weill Cornell Medical College, New York, NY, 10021, USA.
• ⁸ Wellcome Sanger Institute, Wellcome Genome Campus, CB10 1SA, Hinxton, UK.
• ⁹ Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, DD1 4HN, Scotland, UK.
• ¹⁰ Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Faculté de Pharmacie, Malaria Research and Training Center (MRTC), Point G, PB1805, Bamako, Mali. [email protected].
• ¹¹ Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, 10032, USA. [email protected].
• ¹² Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY, 10032, USA. [email protected].
• ¹³ Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA. [email protected].
• ¹⁴ The Kirby Institute, UNSW Sydney, Kensington, NSW, 2052, Australia. [email protected].
• ¹⁵ Global Health Institute of Merck, Ares Trading S.A., (an affiliate of Merck KGaA, Darmstadt, Germany), 1262, Eysins, Switzerland. [email protected].